RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13
RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and raises the price target from $12 to $13.
Read original at benzingaStocks · News reference
Ardent Health Lowers FY2026 GAAP EPS Guidance from $0.90-$1.27 to $0.78-$1.15 vs $1.09 Est; Affirms FY2026 Sales Guidance of $6.400B-$6.700B vs $6.441B Est
Ardent Health (NYSE:ARDT) lowers FY2026 GAAP EPS guidance from $0.90-$1.27 to $0.78-$1.15 vs $1.09 analyst estimate. Affirms FY2026 sales outlook from $6.400 billion-$6.700 billion to $6.400 billion-$6.700 billion vs
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 8:17 PM
- Checked
- Aug 4, 2026, 8:17 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13
Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $12 to $13.
Read original at benzingaGuggenheim Maintains Buy on Ardent Health, Raises Price Target to $14
Guggenheim analyst Jason Cassorla maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $13 to $14.
Read original at benzingaArdent Health shares are trading higher after the company reported better-than-expected Q2 sales results and affirmed its FY26 sales guidance with its midpoint above estimates.
Read original at benzinga